NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma [RNA-seq]
Single-cell RNA-seq · human · 24 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 12 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBlood · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE328216_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1454372 and SRA study SRP692379. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 12 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9675140 KMS-11-100nM-Day14-Rep1 KMS-11-100nM-Day14
- GSM9675141 KMS-11-100nM-Day14-Rep2 KMS-11-100nM-Day14
- GSM9675142 KMS-11-100nM-Day7-Rep1 KMS-11-100nM-Day7
- GSM9675143 KMS-11-100nM-Day7-Rep2 KMS-11-100nM-Day7
- GSM9675144 KMS-11-1uM-Day14-Rep1 KMS-11-1uM-Day14
- GSM9675145 KMS-11-1uM-Day14-Rep2 KMS-11-1uM-Day14
- GSM9675146 KMS-11-1uM-Day7-Rep1 KMS-11-1uM-Day7
- GSM9675147 KMS-11-1uM-Day7-Rep2 KMS-11-1uM-Day7
- GSM9675148 KMS-11-DMSO-Day14-Rep1 KMS-11-DMSO-Day14
- GSM9675149 KMS-11-DMSO-Day14-Rep2 KMS-11-DMSO-Day14
- GSM9675150 KMS-11-DMSO-Day7-Rep1 KMS-11-DMSO-Day7
- GSM9675151 KMS-11-DMSO-Day7-Rep2 KMS-11-DMSO-Day7
- GSM9675152 KMS-34-100nM-Day14-Rep1 KMS-34-100nM-Day14
- GSM9675153 KMS-34-100nM-Day14-Rep2 KMS-34-100nM-Day14
- GSM9675154 KMS-34-100nM-Day7-Rep1 KMS-34-100nM-Day7
- GSM9675155 KMS-34-100nM-Day7-Rep2 KMS-34-100nM-Day7
- GSM9675156 KMS-34-1uM-Day14-Rep1 KMS-34-1uM-Day14
- GSM9675157 KMS-34-1uM-Day14-Rep2 KMS-34-1uM-Day14
- GSM9675158 KMS-34-1uM-Day7-Rep1 KMS-34-1uM-Day7
- GSM9675159 KMS-34-1uM-Day7-Rep2 KMS-34-1uM-Day7
- GSM9675160 KMS-34-DMSO-Day14-Rep1 KMS-34-DMSO-Day14
- GSM9675161 KMS-34-DMSO-Day14-Rep2 KMS-34-DMSO-Day14
- GSM9675162 KMS-34-DMSO-Day7-Rep1 KMS-34-DMSO-Day7
- GSM9675163 KMS-34-DMSO-Day7-Rep2 KMS-34-DMSO-Day7
- GSE328217 NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma 46 samples shares nsd2, degradation, remediates, oncogenic, cistrome, multiple, myeloma
- GSE328215 NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma [ATAC-seq] 22 samples shares nsd2, degradation, remediates, oncogenic, cistrome, multiple, myeloma
- GSE294275 Transcriptional analysis of direct NSD2 target genes in t(4;14) multiple myeloma reveals H3K36me2-dependent regulation and H3K27me3 antagonism [CUT&TAG] 40 samples shares nsd2, multiple, myeloma
- GSE274846 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_SOC) 45 samples shares oncogenic, multiple, myeloma
- GSE222212 TCF4 is a key mediator of cell identity in neuroblastoma and vulnerable to protein degradation by multiple epigenetic factors [RNA-seq] 42 samples shares degradation, multiple, rna-seq
- GSE230466 Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma [ChIP-seq] 61 samples shares oncogenic, multiple, myeloma
- GSE273492 Selective NSD2 Inhibition Reveals an Epigenetic Vulnerability of KRAS-Driven Cancers [RNA-Seq] 36 samples shares nsd2, rna-seq
- GSE242735 NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis [RNA-seq] 32 samples shares nsd2, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.